bevacizumab + oxaliplatin + paclitaxel

This is a combination regimen consisting of three distinct anticancer agents: - **Bevacizumab** is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis and reducing blood supply to tumors. - **Oxaliplatin** is a platinum-based chemotherapeutic agent that forms DNA crosslinks, inhibiting DNA replication and transcription, leading to cell death. - **Paclitaxel** is a microtubule-stabilizing agent that disrupts mitosis by preventing the normal breakdown of microtubules during cell division. This combination does not have an established unique brand or regimen name in major guidelines but represents an investigational or off-label multi-agent chemotherapy protocol. Each component has been used in various approved regimens for solid tumors, particularly colorectal cancer (bevacizumab + oxaliplatin with fluoropyrimidines) and ovarian cancer (bevacizumab + paclitaxel with carboplatin), but the specific triple combination of bevacizumab, oxaliplatin, and paclitaxel together is not standard for any single indication based on current evidence[2][3][4][6]. The mechanism of action involves antiangiogenic effects from bevacizumab combined with cytotoxicity from both oxaliplatin and paclitaxel.

Brand names

AvastinTaxolEloxatin

Other names

IP Oxaliplatin/Paclitaxel + IV Paclitaxel/Bevacizumaboxaliplatin-M.D. Anderson Cancer Center-peritoneal carcinomatosis